This study aims to evaluate the effects of the ProstaThrive™ supplement on lower urinary tract symptoms (LUTS) in men. It is a 90-day virtual, randomized, placebo-controlled trial with 80 male participants aged 40 and above. The primary endpoint is the reduction in LUTS, while secondary endpoints include changes in sexual function and performance.

This is a virtual two-arm randomized placebo-controlled clinical trial lasting 90 days. Participants will take the ProstaThrive™ supplement or a placebo daily and complete questionnaires at Baseline, Day 30, Day 60, and Day 90. The study will assess the efficacy of ProstaThrive™ on LUTS such as urinary urgency, nighttime urination frequency, perceived urinary flow, and bladder emptying, as well as secondary outcomes related to sexual function.

Inclusion Criteria:

• Male participants aged 40+
• Experience symptoms such as frequent nighttime urination, incomplete bladder emptying, weak urinary stream, and frequent daytime urination
• Difficulty in getting or maintaining an erection
• Willing to avoid introducing any new products or medications targeting LUTS or erectile dysfunction during the study period

Exclusion Criteria:

• Recent surgeries or invasive treatments
• History of prostate or male reproductive cancers
• Urinary issues caused by neurological conditions
• Previous surgery on the genitals, prostate, bladder, or urethra
• Known allergies to product ingredients
• Diagnosed with chronic health conditions impacting study participation
• Current substance abuse
• Participation in other clinical trials
• Taking medications or supplements targeting LUTS or erectile dysfunction

Triple (Participant, Investigator, Outcomes Assessor)